drugset
drugset / Trial / NCT03808168

Nivolumab Based Immunotherapy for Treatment of High Grade Cervical Dysplasia

NCT03808168 ↗

Phase 2 Withdrawn University of Texas Southwestern Medical Center
RandomizedSingle-groupOpen-labelTreatment

Summary

The study design is a phase II interventional trial for women with biopsy proven high-grade cervical dysplasia. The study is an open label study and randomized. The study will have two arms. Patients will be randomized to both arms.

Timeline

Start
2019-01-15
Primary completion
2019-06-01
Completion
2020-06-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nivolumab Monoclonal antibody 3 mg/kg Intravenous

Indications

cervix disorder